Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1042 in Japanese patients with malignant solid tumors
jRCT2031230438Phase 1Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tecaginlimab and pembrolizumab in Non-hematologic malignancy (3 arms), sponsored by Genmab. Primary endpoint: Safety and tolerability. Started Nov 2023; status: active, not recruiting.
02
Drugs
tecaginlimabpembrolizumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031230438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230438.